ENDOMETRIY SARATONINING QAYTALOVIDA EVEROLIMUSNI LETROZOL, MEGESTROL ASETAT VA PAKLITAKSEL BILAN KOMBINATSIYASINING SAMARADORLIGI
Abstrakt
Dolzarbligi. Everolimus – mTOR ingibitori, endometriy saratoni davolashda samaradorligi isbotlangan, ammo O‘zbekistonda uning qo‘llanilishi tajribasi cheklangan. Qaytalovchi/metastatik endometriy saratonida standart terapiyaga nisbatan rezistentlik tez-tez rivojlanadi, shuning uchun yangi davolash sxemalari zarur. Tadqiqotning maqsadi. Bunday ayol bemorlar guruhida everolimus bilan kombinatsiyalarning samaradorligi va xavfsizligini baholash. Materiallar va usullar. Retrospektiv, bir markazli tadqiqot (may 2022 – iyun 2024)ga oldin platina/paklitaksel olgan 44 nafar ayol bemor kiritildi. 1-guruh (n = 14) – everolimus 10 mg/kun dozada letrozol, megestrol yoki paklitaksel bilan; 2-guruh (nazorat, n = 30) – xuddi shu sxemalar everolimusisiz. Samaradorlik (RECIST v1.1) va toksisitеt (CTCAE v5.0) har 8 haftada baholandi. Natijalar. Ob’ektiv javob chastotasi 28,6 % ga nisbatan 13,3 % (p = 0,18); kasallikni nazorat qilish – 78,6 % vs 50,0 % (p = 0,047). Progressiyagacha bo‘lgan median vaqt 6,2 oyga oshdi (HR 0,46; p = 0,011), umumiy omon qolish muddati esa 28,0 oyga yetdi (HR 0,55; p = 0,032). Og‘ir stomatit va giperglikemiya har biri 14 % holatda kuzatildi; davolashni faqat 1 ayol bemor to‘xtatdi. Xulosa. Everolimus qo‘shilishi kasallikni nazorat qilishni sezilarli yaxshiladi hamda TTP va OS muddatlarini uzaytirdi, toksisitеt darajasi esa maqbul bo‘lib, bu II faza tadqiqotlari ma’lumotlari bilan mos keladi.
Mualliflar haqida
Adabiyotlar ro'yxati
Bogani G., Chiappa V., Lorusso D., Raspagliesi F. Treatment of Recurrent Endometrial Carcinoma: Progress Toward a More Personalized Approach. Journal of Clinical Oncology. 2015. 33(30), 3516. https://doi.org/10.1200/JCO.2015.61.4636
Pham M., Joseph D., Fellman B. et al. O035/#427 Exploring the role of moelecular aberrations in predicting response to everolimus in the treatment of endometrial cancer. Int J Gynecol Cancer. 2022;32(Suppl 3):A1–A274 A21. https://doi.org/10.1136/ijgc-2022-igcs.37
Ray-Coquard I., Favier L., Weber B. et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. British Journal of Cancer. 2013, 108(9), 1771–1777. https://doi.org/10.1038/BJC.2013.183
Ring K., Celestino J., Yates M. et al. Is Rad/let/met More Than Just a Catchy Name? A Preclinical Evaluation of Everolimus, Letrozole, and Metformin in Recurrent Endometrial Cancer. Gynecologic Oncology. 2014, 134 (2), 429-430. https://doi.org/10.1016/j.ygyno.2014.04.018
Slomovitz B.M., Jiang Y., Yates M.S. et al. Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma. Journal of Clinical Oncology. 2015, 33(8), 930–936. https://doi.org/10.1200/JCO.2014.58.3401
Slomovitz B.M., Brown J., Johnston T.A. et al. Coleman A Phase Ii Study of Everolimus and Letrozole in Patients with Recurrent Endometrial Carcinoma. Journal of Clinical Oncology. 2011, 29:15_suppl, 5012-5012. https://doi.org/10.1200/jco.2011.29.15_suppl.5012
Soliman P.T., Westin Sh.N., Iglesias D.A. et al. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. Clinical Cancer Research. 2020; 26(3), 581–587. https://doi.org/10.1158/1078-0432.CCR-19-0471
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.